Five putative drug resistance parameters (MDR1/P-glycoprotein, MDR- associated protein, glutathione-S-transferase, bcl-2 and topoisomerase IIα) in 57 newly diagnosed acute myeloid leukaemias

European Journal of Haematology

Volumn 59, Issue 4, 1997, Pages 206-215

  Lohri, Andreas ^a   Van Hille, Benoît ^a   Bacchi, Marisa ^b   Fopp, Markus ^c   Joncourt, Franzisca ^d   Reuter, Jürgen ^a   Cerny, Thomas ^d   Fey, Martin F ^d   Herrmann, Richard ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b SIAK Coordinating Center   (Switzerland)

^c Blood Transfusion Service SRK   (Switzerland)

^d UNIVERSITY OF BERN   (Switzerland)

Author keywords

AML; Bcl 2; Drug resistance; Prognostic factors; Topoisomerase II

Indexed keywords

DNA TOPOISOMERASE (ATP HYDROLYSING); GLUTATHIONE TRANSFERASE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLAST TRANSFORMATION; BONE MARROW TRANSPLANTATION; CANCER SURVIVAL; CELL DEATH; CHROMOSOME 16; CLINICAL TRIAL; CYTOSTASIS; DNA REPLICATION; EOSINOPHILIA; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIDRUG RESISTANCE; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; REMISSION; TREATMENT OUTCOME;

EID: 0030770522     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1997.tb00979.x     Document Type: Article

References (58)

1. MAYER RJ, DAVIS RB, SCHIFFER CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B. N Engl J Med 1994: 331: 896-903.
2. ZITTOUN RA, MANDELLI F, WILLEMZE R, et al. Autologous or allogeneic bone marrow transplantation compared with intensive chemotherapy in acute myelogenous leukemia. European Organization for Research and Treatment of Cancer (EORTC) and the Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto (GIMEMA) Leukemia Cooperative Groups. N Engl J Med 1995: 332: 217-223.
3. HOOGE DE. Cytogenetics and oncogenes in leukemia. Curr Opin Oncol 1994: 6: 3-13.
4. DEL POETA G, STASI R, VENDITTI A, et al. Prognostic value of cell marker analysis in de novo acute myeloid leukemia. Leukemia 1994: 8: 388-394.
5. KITA K, MIWA H, NAKASE K, et al. Clinical importance of CD7 expression in acute myelocytic leukemia. The Japan Cooperative Group of Leukemia/Lymphoma. Blood 1993: 81: 2399-2405.
6. GELLER RB, ZAHURAK M, HURWITZ CA, BURKE PJ, KARP JE. Prognostic importance of immunophenotyping in adults with acute myelocytic leukaemia: the significance of the stem-cell glycoprotein CD34 (My10). Br J Haematol 1990: 76: 340-347.
7. LOWENBERG B, VAN PUTTEN WL, TOUW IP, DELWEL R, SANTINI V. Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. N Engl J Med 1993: 328: 614-619.
8. SONNEVELD P. Multidrug resistance in acute myeloid leukaemia. Baillières Clin Haematol 1996: 9: 185-203.
9. MARIE JP, ZHOU DC, GURBUXANI S, LEGRAND O, ZITTOUN R. MDR1/P-glycoprotein in haematological neoplasms. Eur J Cancer 1996: 32: 1034-1038.
10. BELLAMY WT. P-glycoproteins and multidrug resistance. Annu Rev Pharmacol Toxicol 1996: 36: 161-183.
11. HOLMES JA, WEST RR. The effect of MDR-1 gene expression on outcome in acute myeloblastic leukaemia. Br J Cancer 1994: 69: 382-384.
12. COLE SP, BHARDWAJ G, GERLACH JH, et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992: 258: 1650-1654.
13. SCHNEIDER E, HORTON JK, YANG CH, NAKAGAWA M, COWAN KH. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance. Cancer Res 1994: 54: 152-158.
14. BURGER H, NOOTER K, ZAMAN GJ, et al. Expression of the multidrug resistance-associated protein (MRP) in acute and chronic leukemias. Leukemia 1994: 8: 990-997.
15. ZHOU DC, HOANG NGOC L, DELMAR A, et al. Expression of resistance genes in acute leukemia. Leuk Lymph 1994: 13 Suppl 1: 27-30.
16. KUSS BJ, DEELEY RG, COLE SP, et al. Deletion of gene for multidrug resistance in acute myeloid leukaemia with inversion in chromosome 16: prognostic implications. Lancet 1994: 343: 1531-1534.
17. TEW KD. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994: 54: 4313-4320.
18. TIDEFELT U, ELMHORN-ROSENBORG A, PAUL C, HAO X, MANNERVIK B, ERIKSSON LC. Expression of glutathione transferase pi as a predictor for treatment results at different stages of acute nonlymphoblastic leukaemia. Cancer Res 1992: 52: 3281-3285
19. JONCOURT F, OBERLI A, REDMOND SM, et al. Cytostatic drug resistance: parallel assessment of glutathione-based detoxifying enzymes, O6-alkylguanine-DNA-alkyltransferase and P-glycoprotein in adult patients with leukaemia. Br J Haematol 1993: 85: 103-111.
20. GEKELER V, FRESE G, NOLLER A, et al. Mdr1/P-glycoprotein, topoisomerase, and glutathione-S-transferase pi gene expression in primary and relapsed state adult and childhood leukaemias. Br J Cancer 1992: 66: 507-517.
21. MIYASHITA T, REED JC. bcl-2 gene transfer increases relative resistance of S49.1 and WEH17.2 lymphoid cells to cell death and DNA fragmentation induced by glucocorticoids and multiple chemotherapeutic drugs. Cancer Res 1992: 52: 5407-5411.
22. CAMPOS L, ROUAULT JP, SABIDO O, et al. High expression of bcl-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy. Blood 1993: 81: 3091-3096.
23. HOFMANN GA, MATTERN MR. Topoisomerase II in multiple drug resistance. Cytotechnology 1993: 12: 137-154.
24. DRAKE FH, HOFMANN GA, BARTUS HF, MATTERN MR. CROOKE ST, MIRABELLI CK. Biochemical and pharmacological properties of p170 and p180 forms of topoisomerase II. Biochemistry 1989: 28: 8154-8160.
25. EVANS CD, MIRSKI SE, DANKS MK, COLE SP Reduced levels of topoisomerase II alpha and II beta in a multidrug-resistant lung-cancer cell line. Cancer Chemother Pharmacol 1994: 34: 242-248.
26. VAN HILLE B, LOHRI A, REUTER J, HERRMANN R. Nonradioactive quantification of mdr1 mRNA by polymerase chain reaction amplification coupled with HPLC. Clin Chem 1995: 41: 1087-1093.
27. FOPP M, FEY MF, BACCHI M, et al. Post-remission therapy of adult acute myeloid leukaemia: one cycle of high dose versus standard-dose cytarabine. Ann Oncol 1997: 8: 251-257.
28. NAKAJIMA IIJIMA S, HAMADA H, REDDY P, KAKUNAGA T. Molecular structure of the human cytoplasmic beta-actin gene: interspecies homology of sequences in the introns. Proc Natl Acad Sci USA 1985: 82: 6133-6137.
29. CHEN C, CHIN JE, UEDA K, et al. Internal duplication and homology with bacterial transport proteins in the mdr1 (P-glycoprotein) gene from multidrug-resistant human cells. Cell 1986: 47: 381-389.
30. KANO T, SAKAI M, MURAMATSU M. Structure and expression of a human class pi glutathione S-transferase messenger RNA. Cancer Res 1987: 47: 5626-5630.
31. CHUNG TD, DRAKE FH, TAN KB, PER SR, CROOKE ST, MIRABELLI CK. Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc Natl Acad Sci USA 1989: 86: 9431-9435.
32. CLEARY ML, SMITH SD, SKLAR J. Cloning and structural analysis of cDNAs for bcl-2 and a hybrid bcl-2/immunoglobulin transcript resulting from the t(14: 18) translocation. Cell 1986: 47: 19-28.
33. DALTON WS, DURIE BG, ALBERTS DS, GERLACH JH, CRESS AE. Characterization of a new drug-resistant human myeloma cell line that expresses P-glycoprotein. Cancer Res 1986: 46: 5125-5130.
34. RONINSON IB, CHIN JE, CHOI K, et al. Isolation of human mdr DNA sequences amplified in multidrug-resistant KB carcinoma cells. Proc Natl Acad Sci USA 1986: 83: 4538-4542.
35. COLE SP, CHANDA ER, DICKE FP, GERLACH JH, MIRSKI SE. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cancer Res 1991: 51: 3345-3352.
36. BELLAMY WT, DALTON WS, MELTZER P, DORR RT. Role of glutathione and its associated enzymes in multidrug-resistant human myeloma cells. Biochem Pharmacol 1989: 38: 787-793.
37. REDMOND SM, JONCOURT F, BUSER K, et al. Assessment of P-glycoprotein, glutathione-based detoxifying enzymes and O6-alkylguanine-DNA alkyltransferase as potential indicators of constitutive drug resistance in human colorectal tumors. Cancer Res 1991: 51: 2092-2097.
38. TOWBIN H, STAEHLIN T, GORDON J. Electrophoretic transfer of protein from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci USA 1979: 76: 4350-4354.
39. GERSON SL, TREY JE, MILLER K, BERGER NA. Comparison of O6-alkylguanine-DNA alkyltransferase acitivity based on cellular DNA content in human, rat and mouse tissues. Carcinogenesis 1986: 7: 745-749.
40. SIEGEL S. Nonparametric statistics for the behavioral sciences. New York, NY: Mc Graw-Hill, 1956
41. KAPLAN EL, MEIER P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958: 53: 457-481.
42. MANTEL N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966: 50: 163.
43. Cox DR. Regression models and life tables. JR Stat Soc B 1972: 34: 187-220.
44. SAS/STAT Users's Guide, Version 6, Fourth Edition. Cary NC: SAS Institute Inc. 1989.
45. DRACH D, ZHAO S, DRACH J, et al. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood 1992: 80: 2729-2734.
46. MCPHERSON RA. Evolution of polymerase chain reaction to a quantitative laboratory tool. Clin Chem 1995: 41: 1065-1067.
47. CUZICK J. Molecular epidemiology: carcinogens, DNA adducts, and cancer - still a long way to go. J Natl Cancer Inst 1995: 87: 861-862
48. SIMON R. Discovering the truth about tamoxifen: problems of multiplicity in statistical evaluation of biomedical data. J Natl Cancer Inst 1995: 87: 627-629.
49. HINDS M, DEISSEROTH K, MAYES J, et al. Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine-resistant form of topoisomerase II. Cancer Res 1991: 51: 4729-4731.
50. KAUFMANN SH, KARP JE, JONES RJ, et al. Topoisomerase II levels and drug sensitivity in adult acute myelogenous leukemia. Blood 1994: 83: 517-530.
51. MCKENNA SL, WEST RR, WHITTAKER JA, PADUA RA, HOLMES JA. Topoisomerase II alpha expression in acute myeloid leukaemia and its relationship to clinical outcome. Leukemia 1994: 8: 1498-1502.
52. FRY AM, CHRESTA CM, DAVIES SM, et al. Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines. Cancer Res 1991: 51: 6592-6595.
53. MIYASHITA T, KRAJEWSKI S, KRAJEWSKA M, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994: 9: 1799-1805.
54. BECK WT, GROGAN TM, WILLMAN CL, et al. Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations. Cancer Res 1996: 56: 3010-3020.
55. BROXTERMAN HJ, SONNEVELD P, FELLER N, et al. Quality control of multidrug resistance assays in adult acute leukemia: correlation between assays for P-glycoprotein expression and activity. Blood 1996: 87: 4809-4816.
56. PERROT JY, FAUSSAT AM, ZHOU DC, ZITTOUN R, ROBERT J, MARIE JP. Multicentric evaluation of MDR phenotype in leukemia: intermediate analysis of the French study. Bull Cancer 1996: 83: 634-640.
57. ALBERTIONI F, GRUBER A, ARESTRÖM I, VITOLS S. Multidrug resistance gene (mdr1) RNA levels in relation to P-glycoprotein content of leukemic cells from patients with acute leukemia. Med Oncol 1995: 12: 79-86.
58. CLAXTON DF, LIU P, HSU HB, et al. Detection of fusion transcripts generated by the inversion 16 chromosome in acute myelogenous leukemia. Blood 1994: 83: 1750-1756.